Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
Stocktwits on MSN
Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?
With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
COMPASS Pathways plc beats earnings expectations. Reported EPS is $-0.44, expectations were $-0.47. Operator: Ladies and gentlemen, thank you for standing by. And welcome to the COMPASS Pathways First ...
Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback